6533b851fe1ef96bd12a9a99

RESEARCH PRODUCT

Direct Oral Anticoagulants in the Setting of Catheter Ablation of Atrial Fibrillation: State of art

Girolamo MannoGiuseppe CoppolaMirko LuparelliEgle CorradoGianfranco CiaramitaroAntonino MignanoSerge Boveda

subject

medicine.medical_specialtyVitamin Kmedicine.medical_treatmentAdministration OralRhythm controlCatheter ablation030204 cardiovascular system & hematologyVitamin klaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineVitamin K/administration & dosagecatheter ablationmedicineHumansrisk factorsIn patientatrial fibrillation030212 general & internal medicineanticoagulationRandomized Controlled Trials as TopicAnticoagulants/administration & dosagebusiness.industryAnticoagulantsAtrial fibrillationGeneral Medicinemedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareOptimal managementTreatment OutcomeState of artCardiologybusinessCardiology and Cardiovascular MedicineAtrial Fibrillation/complications

description

Atrial fibrillation (AF) represents the arrhythmia of greatest clinical impact and catheter ablation of AF (CAAF) has become the most effective strategy for rhythm control in selected patients. Therefore, appropriate anticoagulation strategies are of paramount importance for patients undergoing CAAF, especially those at high risk, such those with high CHA2DS2VASc scores. Optimal management of anticoagulation before, during, and after CAAF is crucial. Several studies have evaluated the use of different anticoagulation strategies in the periprocedural period. Randomized controlled trial seem to suggest that in patients undergoing CAAF, uninterrupted (or minimally interrupted) direct oral anticoagulants (DOACs) provides an alternative to continuous vitamin K antagonists strategy, with low thromboembolic and bleeding risk.

yearjournalcountryeditionlanguage
2021-03-01
10.1016/j.cpcardiol.2020.100622http://hdl.handle.net/10447/544500